Navigation Links
Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President
Date:11/24/2008

ANN ARBOR, Mich., Nov. 24 /PRNewswire/ -- Terumo Heart, Inc. is pleased to announce the appointment of William Pinon to the position of Chief Executive Officer (C.E.O.) and President, effective immediately. "With its innovative mag-lev technology, Terumo Heart is positioned for a strong leadership role in the future treatment of heart failure. I am excited to lead the acceleration of enrollment in the DuraHeart U.S. Pivotal trials in up to 40 clinical sites, and further capitalize on the commercial potential for DuraHeart's CE Mark in Europe," Mr. Pinon commented. Chisato Nojiri, M.D. Ph.D. will continue to serve as Chairperson of the Board and Chief Medical Officer of Terumo Heart, Inc. Dr. Nojiri has been instrumental in bringing the product from its very early development phase through commercialization in Europe, to the start of the U.S. Pivotal Clinical Trial and recent completion of the Japanese Clinical Trial patient enrollment. Dr. Nojiri will continue her global clinical and scientific focus and leadership.

"With the expansion of our U.S. clinical sites, Terumo Heart is experiencing rapid growth. Mr. Pinon's proven track record in the cardiovascular industry and extensive sales and operational experience, are ideally suited to lead our commercialization efforts in the U.S. and continued growth in Europe," said Dr. Nojiri.

Most recently, Mr. Pinon was C.E.O. of Bioheart, a biotechnology company focused on the development of heart failure therapies and devices. Prior to Bioheart, Mr. Pinon held a variety of positions with Johnson & Johnson including Worldwide Vice President of Sales and Marketing at Cordis Corporation where he oversaw the cardiovascular business including the market leading drug eluting stent, CYPHER (TM). Mr. Pinon received a bachelor's degree in biology from the University of Oregon.

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe.


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. ATS Medical Expands Open Pivot Heart Valve Offerings
4. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
5. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
6. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
9. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
10. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
11. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate ... and Singapore in the latest adipose and bone marrow therapies. , Through ...
(Date:2/9/2016)... ... , ... Date and time: March 1, 2016, 5:30 p.m. ... Center of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The ... open house for participants to learn about a new Master of Biomedical Science ...
(Date:2/9/2016)... CA (PRWEB) , ... February 09, 2016 , ... ... strategic changes over the years and Open Access publishing is one of the ... With its 700+ open access journals and 3000+ International Conferences ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):